Latest Breaking News On - Ichnos sciences - Page 3 : comparemela.com

Rating: neutral; Glenmark: Licensing deal may boost the stock

Rating: neutral; Glenmark: Licensing deal may boost the stock
financialexpress.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from financialexpress.com Daily Mail and Mail on Sunday newspapers.

Ichnos sciences

Stocks in news: Infosys, RITES, Paytm, Persistent Systems, IRCON and more

Stocks to watch out for today: IRCON International, Maruti Suzuki, Infosys, HCL Tech, RITES, Paytm, Persistent Systems, IDBI Bank, Glenmark Pharmaceuticals, HDFC Asset Management Company, Sun Pharma, Advance Lifestyles and more

Sun pharmaMaruti suzukiHathway bhawani cabletel datacomVivanta industriesPaytm payments bankSuzuki motor companyGlenmark pharmaceuticalsCapital servicesGujarat hotelsSun pharmaceutical industriesDen networksCommunications paytmIchnos sciencesRst corporationAsset management companyAsset management co

Glenmark s subsidiary Ichnos Sciences enters into licensing agreement with Astria Therapeutics for its monoclonal antibody portfolio

Glenmark s subsidiary Ichnos Sciences enters into licensing agreement with Astria Therapeutics for its monoclonal antibody portfolio
financialexpress.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from financialexpress.com Daily Mail and Mail on Sunday newspapers.

Jill milneCyril kontoIchnos sciencesGlenmark pharmaceuticalsAstria therapeuticsAstria therapeutic

Glenmark arm inks licensing pact with Astria Therapeutics

With the execution of this agreement, Ichnos has successfully licensed its two assets for inflammatory and immunological diseases, a key milestone in the company s prioritisation of its pipeline of oncology drug candidates, Ichnos Sciences said in a statement filed on BSE by Glenmark.

Jill milneCyril kontoGlenmark pharmaceuticals ltd onIchnos sciencesPharmaceuticals ltdAstria therapeuticsManaging directorAstria therapeuticGlenmark pharmaceuticals

Astria Therapeutics Announces Exclusive Worldwide License Agreement with Ichnos Sciences for OX40 Po

Differentiated Preclinical Lead Candidate STAR-0310 to be Developed as a Potential Best-in-Class Long-Acting Treatment for Atopic Dermatitis – Conference Call and Webcast to be Held on October 12, 2023 at 8:30am ET BOSTON (BUSINESS WIRE) Astria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical company f.

Andrea matthewsInstagram astriatxJillc milneExchange commissionDrug administrationAstria therapeutics incIchnos sciencesPreclinical lead candidatePotential best in class long acting treatmentAtopic dermatitisAstria therapeuticsChief executive officerChief business officerInvestigational new drugAnnual report